Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VBIO files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsValion Bio hires Melinda Lackey as General Counsel with $321K salary and 45K options
Filed May 4, 2026 · Period ending May 1, 2026 · ~1 min read
Key Changes
-
medium
Melinda Lackey, 49, appointed General Counsel and SVP Legal Affairs effective May 1, 2026. She brings 18 years of legal experience including prior roles as SVP Legal at Alaunos Therapeutics and General Counsel at Kuur Therapeutics, a CAR-NKT cellular therapy company.
Item 5.02 verify on EDGAR → -
low
Compensation package includes $321,000 annual base salary, discretionary bonus up to 35% of base (roughly $112K), and stock options for 45,000 shares at fair market value on grant date.
Item 5.02 verify on EDGAR → -
low
Severance terms provide six months base salary continuation and COBRA coverage if terminated without cause or she leaves for good reason after six months of employment, representing potential liability of $321,000 plus benefits.
Item 5.02 verify on EDGAR →
Summary
Valion Bio (formerly Tivic Health Systems) has appointed Melinda Lackey as its new General Counsel and Senior Vice President of Legal Affairs, effective May 1, 2026. The hire brings experienced legal leadership to the biotechnology company, with Lackey's background including senior roles at other biotech firms focused on cellular therapies. Her compensation package is structured with a mix of cash and equity, typical for executive appointments at this level.
For retail investors, this represents a routine but positive development as the company builds out its legal and compliance infrastructure with an experienced executive. The appointment suggests Valion Bio is maturing its corporate governance as it continues operations in the biotech space. Watch for any upcoming regulatory filings or corporate transactions where Lackey's expertise in M&A and corporate law (given her background at Kuur Therapeutics, which was acquired) may signal strategic activity ahead.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
on May 1, 2026, Ms. Lackey was granted an option to purchase 45,000 shares of common stock of the Company with an exercise price equal to the fair market value of a share of common stock of the Company on the grant date.
As part of her compensation package, Ms. Lackey received stock options to purchase 45,000 shares at fair market value on the grant date. This represents equity-based compensation to align her interests with shareholders.
Event · Item 7.01 — Regulation FD Disclosure
Item 7.01 — Regulation FD Disclosure filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On May 4, 2026, the Company issued a press release announcing Ms. Lackey’s appointment as General Counsel and Senior Vice President of Legal Affairs of the Company, among other things.
The company disclosed the appointment of Ms. Lackey to the role of General Counsel and Senior Vice President of Legal Affairs. This is a routine executive appointment announcement furnished under Regulation FD disclosure rules.
Event · Item 9.01 — Financial Statements and Exhibits
Valion Bio entered into an executive employment agreement with Melinda Lackey effective May 1, 2026.
Added in current filing · verify on EDGAR →
Executive Employment Agreement, by and between Valion Bio, Inc. and Melinda Lackey, dated May 1, 2026.
Valion Bio has entered into an executive employment agreement with Melinda Lackey effective May 1, 2026. The specific role, compensation terms, and other material provisions are not disclosed in the 8-K body itself, as the full agreement and certain schedules have been omitted pursuant to Regulation S-K. A press release dated May 4, 2026 was also issued in connection with this announcement.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify